These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17186213)

  • 1. Better days are coming for Riley-Day patients.
    Luft FC
    J Mol Med (Berl); 2007 Feb; 85(2):99-101. PubMed ID: 17186213
    [No Abstract]   [Full Text] [Related]  

  • 2. Kinetin in familial dysautonomia carriers: implications for a new therapeutic strategy targeting mRNA splicing.
    Gold-von Simson G; Goldberg JD; Rolnitzky LM; Mull J; Leyne M; Voustianiouk A; Slaugenhaupt SA; Axelrod FB
    Pediatr Res; 2009 Mar; 65(3):341-6. PubMed ID: 19033881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia.
    Hims MM; Ibrahim EC; Leyne M; Mull J; Liu L; Lazaro C; Shetty RS; Gill S; Gusella JF; Reed R; Slaugenhaupt SA
    J Mol Med (Berl); 2007 Feb; 85(2):149-61. PubMed ID: 17206408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs.
    Lee G; Papapetrou EP; Kim H; Chambers SM; Tomishima MJ; Fasano CA; Ganat YM; Menon J; Shimizu F; Viale A; Tabar V; Sadelain M; Studer L
    Nature; 2009 Sep; 461(7262):402-6. PubMed ID: 19693009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ELP1 Splicing Correction Reverses Proprioceptive Sensory Loss in Familial Dysautonomia.
    Morini E; Gao D; Montgomery CM; Salani M; Mazzasette C; Krussig TA; Swain B; Dietrich P; Narasimhan J; Gabbeta V; Dakka A; Hedrick J; Zhao X; Weetall M; Naryshkin NA; Wojtkiewicz GG; Ko CP; Talkowski ME; Dragatsis I; Slaugenhaupt SA
    Am J Hum Genet; 2019 Apr; 104(4):638-650. PubMed ID: 30905397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia.
    Axelrod FB; Liebes L; Gold-Von Simson G; Mendoza S; Mull J; Leyne M; Norcliffe-Kaufmann L; Kaufmann H; Slaugenhaupt SA
    Pediatr Res; 2011 Nov; 70(5):480-3. PubMed ID: 21775922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide analysis of familial dysautonomia and kinetin target genes with patient olfactory ecto-mesenchymal stem cells.
    Boone N; Bergon A; Loriod B; Devèze A; Nguyen C; Axelrod FB; Ibrahim EC
    Hum Mutat; 2012 Mar; 33(3):530-40. PubMed ID: 22190446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial treatment increases IKAP levels in human cells generated from Familial Dysautonomia patients.
    Yannai S; Zonszain J; Donyo M; Ast G
    PLoS One; 2019; 14(3):e0211602. PubMed ID: 30889183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Riley-Day Syndrome (congenital familial dysautonomia).
    Keith CG
    Br J Ophthalmol; 1965 Dec; 49(12):667-72. PubMed ID: 5853507
    [No Abstract]   [Full Text] [Related]  

  • 10. Riley-Day syndrome (familial dysautonomia). Survey of 27 cases.
    Goldstein-Nieviazhski C; Wallis K
    Ann Paediatr; 1966; 206(3):188-94. PubMed ID: 5953423
    [No Abstract]   [Full Text] [Related]  

  • 11. Familial dysautonomia or the Riley-Day syndrome.
    Smithells RW
    Dev Med Child Neurol; 1967 Apr; 9(2):234-5. PubMed ID: 6059324
    [No Abstract]   [Full Text] [Related]  

  • 12. Familial dysautonomia (Riley-Day syndrome).
    Howard RO
    Am J Ophthalmol; 1967 Sep; 64(3):392-8. PubMed ID: 6036298
    [No Abstract]   [Full Text] [Related]  

  • 13. Case scenario: perioperative administration of tocotrienols and green tea extract in a child with familial dysautonomia.
    Cook-Sather SD; Viola L; Zur KB; Rubin BY
    Anesthesiology; 2012 Sep; 117(3):639-45. PubMed ID: 22850346
    [No Abstract]   [Full Text] [Related]  

  • 14. Index of suspicion. Case 3. Diagnosis: Riley-Day syndrome (familial dysautonomia [FD]).
    Harrington J; Gianos E; Stiefel M
    Pediatr Rev; 2000 Jul; 21(7):243, 246-7. PubMed ID: 10979825
    [No Abstract]   [Full Text] [Related]  

  • 15. Evidence for autonomic denervation in familial dysautonomia, the Riley-Day syndrome.
    Shinebourne E; Turner P; Sneddon JM
    Br Med J; 1967 Oct; 4(5571):91-2. PubMed ID: 6047852
    [No Abstract]   [Full Text] [Related]  

  • 16. Modelling familial dysautonomia in human induced pluripotent stem cells.
    Lee G; Studer L
    Philos Trans R Soc Lond B Biol Sci; 2011 Aug; 366(1575):2286-96. PubMed ID: 21727134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Riley-Day syndrome. Ocular manifestations in a 35-year-old patient.
    Boruchoff SA; Dohlman CH
    Am J Ophthalmol; 1967 Mar; 63(3):523-4. PubMed ID: 6019543
    [No Abstract]   [Full Text] [Related]  

  • 18. Anaesthesia for a patient suffering from familial dysautonomia (Riley-Day syndrome). Case report.
    Inkster JS
    Br J Anaesth; 1971 May; 43(5):509-12. PubMed ID: 5556864
    [No Abstract]   [Full Text] [Related]  

  • 19. Early diagnosis of familial dysautonomia. Case report with special reference to primary patho-physiological findings.
    Goodall J; Shinebourne E; Lake BD
    Arch Dis Child; 1968 Aug; 43(230):455-8. PubMed ID: 5661874
    [No Abstract]   [Full Text] [Related]  

  • 20. The Riley-Day syndrome--observations on genetics and survivorship. An interim report.
    McKusick VA; Norum RA; Farkas HJ; Brunt PW; Mahloudji M
    Isr J Med Sci; 1967; 3(3):372-9. PubMed ID: 5317548
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.